Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study

Breast Cancer Research

Volumn 12, Issue 2, 2010, Pages

  Cronin Fenton, Deirdre P ^a   Pedersen, Lars ^a   Lash, Timothy L ^a,b   Friis, Søren ^c   Baron, John A ^d   Sørensen, Henrik T ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; VALDECOXIB;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; DATA BASE; DRUG MEGADOSE; FEMALE; HEALTH CARE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; TREATMENT DURATION; BREAST TUMOR; CASE CONTROL STUDY; DENMARK; DRUG UTILIZATION; FACTUAL DATABASE; MIDDLE AGED; RISK; RISK FACTOR; STATISTICS; TIME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DENMARK; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TIME FACTORS;

EID: 77955670093     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2482     Document Type: Article

References (88)

1. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003, 3:28. 10.1186/1471-2407-3-28, 272929, 14588079.
2. Grau MV, Rees JR, Baron JA. Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 2006, 98:281-287. 10.1111/j.1742-7843.2006.pto_294.x, 16611203.
3. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006, 6:130-140. 10.1038/nrc1801, 16491072.
4. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006, 94:346-350. 10.1038/sj.bjc.6602942, 2361146, 16421592.
5. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10:501-507. 10.1016/S1470-2045(09)70035-X, 19410194.
6. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569. 10.1074/jbc.M010787200, 11278747.
7. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 2007, 121:211-215. 10.1002/ijc.22656, 17330846.
8. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005, 162:165-170. 10.1093/aje/kwi182, 15972932.
9. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001, 21:3425-3432.
10. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005, 13:559-583.
11. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002, 29:111-119.
12. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997, 73:371-380. 10.1002/(SICI)1097-0215(19971104)73:3<371::AID-IJC12>3.0.CO;2-G, 9359485.
13. Mustafa A, Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 2008, 14:4935-4942. 10.1158/1078-0432.CCR-08-0958, 2587271, 18676768.
14. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000, 91:886-892.
15. Howe LR, Lippman SM. Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 2008, 100:1420-1423. 10.1093/jnci/djn347, 2567416, 18840814.
16. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006, 55:115-122. 10.1136/gut.2004.047100, 1856377, 16118353.
17. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007, 9:210. 10.1186/bcr1678, 2206709, 17640394.
18. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004, 31:64-73. 10.1053/j.seminoncol.2004.01.008, 15052544.
19. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309. 10.1016/S0140-6736(09)60243-9, 19328542.
20. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG, Weissfeld JL. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008, 17:680-687. 10.1158/1055-9965.EPI-07-2739, 18349287.
21. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999, 91:629-634. 10.1093/jnci/91.7.629, 10203283.
22. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004, 64:6814-6819. 10.1158/0008-5472.CAN-04-1870, 15375001.
23. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488. 10.1200/JCO.2006.07.6356, 17372279.
24. McTiernan A, Wu L, Barnabei VM, Chen C, Hendrix S, Modugno F, Rohan T, Stanczyk FZ, Wang CY. Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Res Treat 2008, 108:217-231. 10.1007/s10549-007-9588-6, 18297397.
25. Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA. Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:1564-1595. 10.1158/1055-9965.EPI-07-2828, 18628410.
26. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53:1322-1327.
27. Khuder SA, Mutgi AB. Breast cancer and NSAID use: ameta-analysis. Br J Cancer 2001, 84:1188-1192. 10.1054/bjoc.2000.1709, 2363879, 11336469.
28. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 2008, 17:115-124. 10.1002/pds.1503, 17955496.
29. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008, 100:1439-1447. 10.1093/jnci/djn324, 18840819.
30. Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 2009, 117:141-150.
31. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005, 97:805-812.
32. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007, 99:881-889. 10.1093/jnci/djk200, 17551148.
33. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002, 22:303-309. 10.1592/phco.22.5.303.33189, 11898889.
34. Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol 2007, 22:319-325. 10.1007/s10654-007-9135-0, 17487555.
35. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 2009, 169:115-121. discussion 121, 10.1001/archinternmed.2008.537, 2632770, 19171806.
36. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Bmj 2000, 320:1642-1646. 10.1136/bmj.320.7250.1642, 27410, 10856067.
37. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692. 10.1038/sj.bjc.6600945, 2377131, 12771981.
38. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008, 17:88-96. 10.1097/CEJ.0b013e3282b6fd55, 18287865.
39. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998, 7:869-873.
40. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996, 88:988-993. 10.1093/jnci/88.14.988, 8667430.
41. Gierach GL, Lacey JV, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA. Nonsteroidal anti-inflammatorydrugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008, 10:R38. 10.1186/bcr2089, 2397540, 18447943.
42. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U. S. cohort. Cancer Epidemiol Biomarkers Prev 2005, 14:261-264. 10.1158/1055-9965.EPI-05-0472, 15668504.
43. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Bmj 1989, 299:1247-1250. 10.1136/bmj.299.6710.1247, 1838122, 2513898.
44. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004, 91:525-529. 10.1038/sj.bjc.6602003, 2409835, 15226764.
45. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 2007, 166:1150-1158. 10.1093/aje/kwm195, 17698973.
46. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Jama 2004, 291:2433-2440. 10.1001/jama.291.20.2433, 15161893.
47. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6:27. 10.1186/1471-2407-6-27, 1373658, 16445867.
48. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999, 6:71-73.
49. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003, 63:6096-6101.
50. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996, 7:203-205. 10.1097/00001648-199603000-00017, 8834563.
51. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 2007, 166:709-716. 10.1093/aje/kwm216, 17660454.
52. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003, 14:915-922. 10.1023/B:CACO.0000007973.59863.66, 14750530.
53. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000, 83:112-120. 10.1054/bjoc.2000.1119, 2374529, 10883678.
54. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999, 29:72-76. 10.1006/pmed.1999.0518, 10446030.
55. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:1586-1591.
56. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007, 16:747-755. 10.1158/1055-9965.EPI-06-0667, 17416766.
57. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005, 68:40-47. 10.1159/000084818, 15802928.
58. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146. 10.1097/00001648-199403000-00003, 8172988.
59. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005, 5:159. 10.1186/1471-2407-5-159, 1334211, 16343343.
60. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008, 62:444-449. 10.1111/j.1742-1241.2007.01668.x, 18194278.
61. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-890. 10.1056/NEJMoa021633, 12621132.
62. Danmarks Statistik. , http://www.dst.dk
63. Danish, Medicines Agency Danish Medicines Agency 2010, Danish, Medicines Agency., http://www.dkma.dk
64. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006, 53:441-449.
65. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997, 44:445-448.
66. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46:263-268.
67. Sorensen H, Christensen T, Schlosser HK, Pedersen L, . (eds) Use of Medical Databases in Clinical Epidemiology. 2009, Aarhus, Denmark: Department of Clinical Epidemiology, Aarhus University Hospital, (eds).
68. Frank L. Epidemiology. When an entire country is a cohort. Science 2000, 287:2398-2399. 10.1126/science.287.5462.2398, 10766613.
69. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. 10.1016/S0140-6736(03)14596-5, 12927427.
70. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993, 168:1473-1480.
71. Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sorensen HT, Pedersen L, McLaughlin JK, Olsen JH. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005, 92:1293-1297. 10.1038/sj.bjc.6602472, 2361963, 15785751.
72. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007, 166:348-354. 10.1093/aje/kwm070, 17504779.
73. Blot WJ, Fischer T, Nielsen GL, Friis S, Mumma M, Lipworth L, DuBois R, McLaughlin JK, Sorensen HT. Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci 2004, 26:319-323. 10.1007/s11096-004-9008-5, 15683100.
74. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development andvalidation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
75. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619. 10.1016/0895-4356(92)90133-8, 1607900.
76. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007, 133:755-760. 10.1053/j.gastro.2007.06.014, 17678921.
77. Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007, 46:265-272.
78. Christensen S, Riis A, Norgaard M, Thomsen RW, Sorensen HT. Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Aliment Pharmacol Ther 2007, 25:907-912.
79. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008, 17:822-833. 10.1002/pds.1592, 18383428.
80. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983, 118:865-886.
81. Arellano FM. The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 2005, 14:213-217. 10.1002/pds.1077, 15724267.
82. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj 2006, 332:1302-1308. 10.1136/bmj.332.7553.1302, 1473048, 16740558.
83. Lagakos SW. Time-to-event analyses for long-term treatments--the APPROVe trial. N Engl J Med 2006, 355:113-117. 10.1056/NEJMp068137, 16801354.
84. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613. 10.1016/S0140-6736(07)60747-8, 17499602.
85. Lokkegaard EL, Johnsen SP, Heitmann BL, Stahlberg C, Pedersen AT, Obel EB, Hundrup YA, Hallas J, Sorensen HT. The validity ofself-reported use of hormone replacement therapy among Danish nurses. Acta Obstet Gynecol Scand 2004, 83:476-481.
86. Osterlind A, Jensen OM. [Evaluation of cancer registration in Denmark in 1977. Preliminary evaluation of cancer registration by the Cancer Register and the National Patient Register]. Ugeskr Laeger 1985, 147:2483-2488.
87. Colditz G, Baer HJ, Tamimi RM. Breast Cancer. Cancer Epidemiology and Prevention 2006, New York: Oxford University Press, Inc., Schottenfeld D, Fraumeni JF, Third.
88. Mellemkjaer L, Blot WJ, Sorensen HT, Thomassen L, McLaughlin JK, Nielsen GL, Olsen JH. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002, 53:173-181. 10.1046/j.0306-5251.2001.01220.x, 1874281, 11851641.